Ranibizumab
Ranibizumab
Definition
A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.
Also known as Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain, Lucentis, RANIBIZUMAB — per NCIT
Also identified as
- ATC S01LA04 per RXNORM
- NCIT NCIT:C67562 per NCIT
- SCTID 422456007 per RXNORM
- SCTID 425256004 per RXNORM
- UNII ZL1R02VT79 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Diabetic retinopathy | may treat | MEDRT · Public domain (U.S. Government work) |
| Retinal vein occlusion | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Camera-type eye | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Retina | may treat a disease of this organ | DERIVED · CC BY 4.0 |
3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.